Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Cancer preventive vaccine showed promising results in preclinical model of Lynch syndrome

AACR 2019

29 Mar - 3 Apr 2019

Published: 11 Apr 2019

Views: 1720

Rating:

Save

Prof Steven Lipkin - Weill Cornell Medical College, New York, USA

Prof Steven Lipkin gives a press conference at AACR 2019 on the findings of a study showing vaccination improves survival in a mouse model of Lynch Syndrome.

Related Videos

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients

Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients ( Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea )

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC

Dr Thierry André - Sorbonne Université, Paris, France

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC ( Dr Thierry André - Sorbonne Université, Paris, France )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

More from ecancer